Stocktoria
Silo Pharma, Inc. SILO
Silo Pharma, Inc. (SILO) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $72,102 at a -5863.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.886 |
| Retained earnings / assets | -2.563 |
| EBIT / assets | -0.563 |
| Equity / liabilities | 4.852 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SILO | Silo Pharma, Inc. | 2/9 | -1.23 | — | — |
| INO | INOVIO PHARMACEUTICALS, INC. | — | — | — | — |
| CNTB | Connect Biopharma Holdings Ltd | 1/9 | — | — | -99.8% |
| AVTX | Avalo Therapeutics, Inc. | 1/9 | -8.95 | — | — |
| IXHL | Incannex Healthcare Inc. | 2/9 | — | — | — |
| HCWB | HCW Biologics Inc. | 2/9 | — | — | — |
| ATNM | Actinium Pharmaceuticals, Inc. | 2/9 | — | — | — |
About Silo Pharma, Inc.
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
FAQ
Is SILO financially healthy?
Silo Pharma, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does SILO pay a dividend?
No, Silo Pharma, Inc. does not currently pay a dividend.
How profitable is SILO?
In FY2025, Silo Pharma, Inc. had a net margin of -5863.5% and a return on equity of -67.0%.
Is SILO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Silo Pharma, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.